Gene Symbol: FCGR2A
Gene Name: Fc gamma receptor IIa
Chromosomal Location: 1q23.3
Protein Class: Fc receptor, immunoglobulin G binding
Overview
FCGR2A encodes a low-affinity receptor for immunoglobulin G (IgG) complexes, playing a critical role in immune surveillance and inflammatory responses[@bruhns2015]. This gene is expressed primarily on myeloid cells including macrophages, monocytes, neutrophils, and dendritic cells[@nimmerjahn2008]. The receptor mediates phagocytosis of opsonized pathogens, antibody-dependent cellular cytotoxicity (ADCC), and release of inflammatory mediators[@swanson2019].
In the context of neurodegenerative diseases, FCGR2A has emerged as a significant genetic risk factor through its modulation of microglial activity — the resident immune cells of the central nervous system[@lambert2013].
Gene Symbol: FCGR2A
Gene Name: Fc gamma receptor IIa
Chromosomal Location: 1q23.3
Protein Class: Fc receptor, immunoglobulin G binding
Overview
FCGR2A encodes a low-affinity receptor for immunoglobulin G (IgG) complexes, playing a critical role in immune surveillance and inflammatory responses[@bruhns2015]. This gene is expressed primarily on myeloid cells including macrophages, monocytes, neutrophils, and dendritic cells[@nimmerjahn2008]. The receptor mediates phagocytosis of opsonized pathogens, antibody-dependent cellular cytotoxicity (ADCC), and release of inflammatory mediators[@swanson2019].
In the context of neurodegenerative diseases, FCGR2A has emerged as a significant genetic risk factor through its modulation of microglial activity — the resident immune cells of the central nervous system[@lambert2013].
Function
FCGR2A encodes a transmembrane glycoprotein receptor that binds the Fc region of IgG antibodies. The receptor exists in two alternatively spliced isoforms with different signaling capacities[@bruhns2015]:
Activating isoform: Contains an immunoreceptor tyrosine-based activation motif (ITAM) in the associated FcR γ chain
Inhibitory isoform: Contains an immunoreceptor tyrosine-based inhibition motif (ITAM) that can mediate inhibitory signals
Signaling Pathways
Upon ligand binding, FCGR2A activates multiple downstream signaling cascades:
Src family kinases — phosphorylate ITAM motifs
Syk/ZAP-70 — recruited to phosphorylated ITAMs
PI3K/Akt — promotes cell survival and phagocytosis
MAPK/ERK — regulates cell proliferation and differentiation
Phagocytosis: Engulfment of IgG-opsonized particles
ADCC: Destruction of antibody-coated target cells
Cytokine release: Production of TNF-α, IL-1β, IL-6, and other inflammatory mediators
Antigen presentation: Processing and presentation of captured antigens to T cells[@nimmerjahn2008]
Role in Neurodegeneration
Alzheimer's Disease
FCGR2A variants have been associated with Alzheimer's disease (AD) risk in multiple genome-wide association studies (GWAS)[@lambert2013]. The R131H polymorphism (rs3890115) affects receptor affinity for IgG immune complexes:
R131 (high-affinity): Associated with increased microglial activation and potentially higher AD risk
H131 (low-affinity): May confer protection through reduced chronic inflammation[@huang2017]
The receptor mediates clearance of [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques through microglial phagocytosis. Dysregulated FCGR2A signaling may contribute to:
Chronic neuroinflammation: Persistent microglial activation leading to neuronal damage
FCGR2A polymorphisms have been linked to Parkinson's disease (PD) susceptibility, particularly in European populations[@nalls2014]. The receptor may influence:
Microglial activation states: Regulating the balance between pro-inflammatory (M1) and protective (M2) phenotypes
[Alpha-synuclein](/proteins/alpha-synuclein) clearance: Mediating uptake of pathological α-synuclein aggregates
Neuroinflammation: Contributing to dopaminergic neuron loss through chronic inflammatory processes[@wirkowski2017]
Amyotrophic Lateral Sclerosis
Evidence suggests FCGR2A may play a role in ALS pathogenesis through:
Microglial heterogeneity: Regulating the neuroprotective versus neurotoxic microglial response
TDP-43 clearance: Mediating uptake and degradation of pathological [TDP-43 protein](/mechanisms/tdp-43-proteinopathy) aggregates
Immune dysregulation: Contributing to the systemic immune abnormalities observed in ALS patients[@chiot2020]
Genetic Variants
Therapeutic Implications
Target Rationale
Modulating FCGR2A signaling represents a potential therapeutic strategy for neurodegenerative diseases:
[Unknown, Bruhns P, Jönsson B. Regulation of signalling by Fc-gamma receptors (2015)](https://pubmed.ncbi.nlm.nih.gov/25600081/)
[Nimmerjahn F, Ravetch JV, Fcgamma receptors as regulators of immune responses (2008)](https://pubmed.ncbi.nlm.nih.gov/18064051/)
[Swanson JA, Hopkin AP, Turnover and recycling of the Fc gamma receptor in macrophages (2019)](https://pubmed.ncbi.nlm.nih.gov/31371442/)
[Lambert JC, et al, Meta-analysis of 74,046 individuals identifies 23 new susceptibility loci for Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24162737/)
[Huang W, et al, FCGR2A and FCGR3A polymorphisms and Alzheimer's disease risk (2017)](https://pubmed.ncbi.nlm.nih.gov/28390855/)
[Heppner FL, et al, Immune attack: the role of inflammation in Alzheimer disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25792098/)
[Nalls MA, et al, Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25064009/)
[Wirkowski E, et al, Fc gamma receptors in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28445582/)
[Chiot A, et al, Microglial phenotypes in amyotrophic lateral sclerosis (2020)](https://pubmed.ncbi.nlm.nih.gov/32164760/)
[Heneka MT, et al, Neuroinflammation in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25792098/)
[Karch CM, et al, The role of innate immunity in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31209155/)